Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New needle treatment could replace surgery for curing Hormone-Driven high blood pressure

NCT ID NCT05405101

Cure Sponsor: Queen Mary University of London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests if a less invasive needle-based treatment (thermal ablation) works as well as surgery to cure a hormone disorder called primary aldosteronism, which causes high blood pressure. About 122 adults with the condition will be randomly assigned to one of the two treatments. The goal is to see if the needle treatment can normalize blood pressure and hormone levels without the need for long-term medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

112 people

The number who actually took part.

Started

Sep 2022

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria (all of): * Age \> 18 years * Primary aldosteronism diagnosed according to international guidelines * Unilateral disease by AVS or PET-CT criteria * Ipsilateral radiological abnormality with benign imaging characteristics and technically amenable to both thermal ablation and surgery * Able and willing to give informed consent * Randomisation approved by MDT Exclusion criteria (any of): * Absolute contraindication to α- or β-adrenoceptor antagonist therapy or CT contrast * Contraindication or unwillingness for either surgery or thermal ablation * Inability to withdraw β-adrenoceptor antagonist therapy for 2 weeks * Unwilling to undergo either LA or thermal ablation * Unwilling to comply with study visit schedule * Pregnancy or unwillingness to undertake secure contraception for the study duration (female participants only) * Life-limiting comorbidity (at the discretion of the PI) * Clinical and/or biochemical evidence of autonomous cortisol secretion sufficient, in the opinion of the patient's physician, to mandate a unilateral adrenalectomy independent of autonomous aldosterone secretion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary aldosteronism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperaldosteronism primary aldosteronism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary aldosteronism

Contacts and locations

Locations

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, SMLG, CB2 0QQ, United Kingdom

  • Guy's and St Thomas' NHS Foundation Trust

    London, SE1 9RT, United Kingdom

  • Imperial College Healthcare NHS Trust

    London, W12 0HS, United Kingdom

  • Sheffield Teaching Hospitals NHS Foundation Trust

    Sheffield, S10 2JF, United Kingdom

  • St Bartholomew's Hospital

    London, EC1A 7BE, United Kingdom

  • University College London Hospital NHS Foundation Trust

    London, NW1 2PG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.